对HER2向抗体二次性血小板缺血的血栓蛋白质受体激动剂药物结合物
Michael Rainone1,2, Saro Kasparian1,2, Tina Nguyen2
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
The oncologist
|June 19, 2023
概括
来自trastuzumab emtansine或trastuzumab deruxtecan的血小板减少可以延迟癌症治疗. 血栓形成素受体激活剂 (TPO-RAs) 帮助6名乳腺癌患者在经历了这种副作用后恢复治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 特拉斯图祖马布埃姆坦辛和特拉斯图祖马布德鲁克斯坦是乳腺癌和其他固体瘤的关键治疗方法.
- 血小板减少 (低血小板数) 是一个常见的不良事件,通常需要延迟治疗或减少剂量.
- 血栓形成素受体激动剂 (TPO-RAs) 在治疗这种特定并发症的有效性尚未得到充分证实.
研究的目的:
- 评估TPO-RAs在患有乳腺癌的患者中发挥的作用.
- 评估TPO-RA干预是否可以促进继续治疗trastuzumab emtansine或trastuzumab deruxtecan.
主要方法:
- 一系列6名乳腺癌患者的病例被追溯审查.
- 患者经历了剂量减少或治疗延迟,原因是因特拉斯图祖马布埃姆坦辛或特拉斯图祖马布德鲁克斯泰康诱导的血小板缺血.
- 这些患者接受了TPO-RAs干预治疗.
主要成果:
- 病例系列中的所有6名患者都经历了血小板缺血,需要改变治疗.
- 在TPO-RAs的干预后,所有患者都能够恢复他们处方的基于trastuzumab的治疗.
- 在所有评估的病例中,TPO-RA支持使治疗的继续成为可能.
结论:
- 血栓形成素受体激活剂可能是治疗trastuzumab emtansine或trastuzumab deruxtecan治疗的患者的血栓缩的可行选择.
- 使用TPO-RA可能会减轻治疗中断,使患者能够完成瘤治疗.
- 需要进一步的前性研究来证实TPO-RAs在这种临床环境中的作用和最佳使用.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
01:27Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212